Overview

Japanese phase1 Study of Belimumab (IV vs SC)

Status:
Completed
Trial end date:
2012-04-11
Target enrollment:
Participant gender:
Summary
This study is an open-label, randomized, 2 parallel group, single dose study in healthy Japanese males to assess the pharmacokinetics and safety/tolerability of single intravenous administration and single subcutaneous administration of GSK1550188. Serial blood samples for the determination of GSK1550188 concentration will be collected and safety assessments will be performed for each treatment group
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Belimumab